PR1 is overexpressed on myeloid leukemia cells, and we have demonstrated the ability and efficacy of targeting the PR1 peptide bound to HLA-A2 on AML blasts by using PR1 peptide as a vaccine in a clinical trial, PR1-specific cytotoxic T lymphocytes, using a first-in-class T cell receptor-like monoclonal antibody named Hu8F4, and a bispecific CD3/Hu8F4 antibody(10–14). Here, TMEM37 is linked to acute myeloid leukemia.